Home > Insider Trading > Filing (0001609351-17-000100)

Filing Details

Accession Number:: 0001609351-17-000100
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-09-06 17:32:41
Reporting Period:: 2017-09-05

Accepted Time:: 2017-09-06 16:32:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609351	Spark Therapeutics Inc.	ONCE	Biological Products, (No Disgnostic Substances) (2836)	462654405

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1673526	Joseph Barge La	3737 Market Street Suite 1300 Philadelphia PA 19104	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-09-05	5,500	$3.45	10,825	No	4	M	Direct
Common Stock	Disposition	2017-09-05	2,500	$81.20	8,325	No	4	S	Direct
Common Stock	Disposition	2017-09-05	990	$80.15	7,335	No	4	S	Direct
Common Stock	Disposition	2017-09-05	2,010	$81.17	5,325	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2017-09-05	5,500	$0.00	5,500	$3.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,171		2024-07-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	200	Indirect	Held by Reporting Person's immediate family members

Footnotes

The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.64, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.85 to $80.54, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.95 to $81.47, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
25% vests May 24, 2015 and the remainder vests in equal quarterly installments over the following three years following May 24, 2015.